Cardinal Health (CAH) Q4 FY26 earnings call

Cardinal Health concluded FY26 with strong Q4 results, driven by robust performance in Pharmaceutical and Specialty Solutions and continued progress in Global Medical Products and Distribution. The company delivered significant profit and free cash flow growth, reaffirming its long-term EPS growth rate while strategically investing in key growth areas. Management remains focused on operational execution and disciplined capital allocation, including a new $5 billion share repurchase authorization.